PKD1 Inhibits AMPKα2 through Phosphorylation of Serine 491 and Impairs Insulin Signaling in Skeletal Muscle Cells

AMP-activated protein kinase (AMPK) is an energy-sensing enzyme whose activity is inhibited in settings of insulin resistance. Exposure to a high glucose concentration has recently been shown to increase phosphorylation of AMPK at Ser485/491 of its α1/α2 subunit; however, the mechanism by which it d...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of biological chemistry 2016-03, Vol.291 (11), p.5664-5675
Main Authors: Coughlan, Kimberly A., Valentine, Rudy J., Sudit, Bella S., Allen, Katherine, Dagon, Yossi, Kahn, Barbara B., Ruderman, Neil B., Saha, Asish K.
Format: Article
Language:English
Subjects:
Akt PKB
AMP-activated kinase (AMPK)
AMP-Activated Protein Kinases - metabolism
Animals
Cell Line
Insulin - metabolism
insulin resistance
Metabolism
Mice
Muscle Fibers, Skeletal - cytology
Muscle Fibers, Skeletal - metabolism
Muscle, Skeletal - cytology
Muscle, Skeletal - metabolism
Phosphorylation
protein kinase C (PKC)
Protein Kinase C - metabolism
protein kinase D (PKD)
Serine - metabolism
Serine485/491
Signal Transduction
skeletal muscle
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:AMP-activated protein kinase (AMPK) is an energy-sensing enzyme whose activity is inhibited in settings of insulin resistance. Exposure to a high glucose concentration has recently been shown to increase phosphorylation of AMPK at Ser485/491 of its α1/α2 subunit; however, the mechanism by which it does so is not known. Diacylglycerol (DAG), which is also increased in muscle exposed to high glucose, activates a number of signaling molecules including protein kinase (PK)C and PKD1. We sought to determine whether PKC or PKD1 is involved in inhibition of AMPK by causing Ser485/491 phosphorylation in skeletal muscle cells. C2C12 myotubes were treated with the PKC/D1 activator phorbol 12-myristate 13-acetate (PMA), which acts as a DAG mimetic. This caused dose- and time-dependent increases in AMPK Ser485/491 phosphorylation, which was associated with a ∼60% decrease in AMPKα2 activity. Expression of a phosphodefective AMPKα2 mutant (S491A) prevented the PMA-induced reduction in AMPK activity. Serine phosphorylation and inhibition of AMPK activity were partially prevented by the broad PKC inhibitor Gö6983 and fully prevented by the specific PKD1 inhibitor CRT0066101. Genetic knockdown of PKD1 also prevented Ser485/491 phosphorylation of AMPK. Inhibition of previously identified kinases that phosphorylate AMPK at this site (Akt, S6K, and ERK) did not prevent these events. PMA treatment also caused impairments in insulin-signaling through Akt, which were prevented by PKD1 inhibition. Finally, recombinant PKD1 phosphorylated AMPKα2 at Ser491 in cell-free conditions. These results identify PKD1 as a novel upstream kinase of AMPKα2 Ser491 that plays a negative role in insulin signaling in muscle cells. Background: Diminished activity of the enzyme AMP-activated protein kinase (AMPK) is associated with impaired insulin signaling. Results: Protein Kinase (PK)C/D1 activation inhibits AMPKα2 via Ser491 phosphorylation; PKD1 inhibition prevents this in skeletal muscle cells. Conclusion: PKD1 is a novel upstream AMPK-kinase that phosphorylates AMPK on Ser491 and regulates insulin signaling. Significance: PKD1 inhibition may be a novel strategy for improving insulin sensitivity.
ISSN:0021-9258
1083-351X
DOI:10.1074/jbc.M115.696849